Open AccessLong-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy
Author(s) -
Chouhei Sakakura,
Akeo Hagiwara,
Koichi Soga,
Koji Miyagawa,
Satoru Nakashima,
Tsuneo Yoshikawa,
Shuichi Kin,
Yuen Nakase,
Nobuki Yamaoka,
Yoshihiko Sagara,
Hisakazu Yamagishi
Publication year - 2006
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v12.i17.2793
Subject(s) - gist , medicine , imatinib , imatinib mesylate , hepatectomy , stromal tumor , tyrosine kinase inhibitor , gastroenterology , metastasis , tyrosine kinase , stromal cell , oncology , surgery , receptor , cancer , resection , myeloid leukemia
Constitutive activation of KIT receptor tyrosine kinase is a critical factor in the pathogenesis of gastrointestinal stromal tumors (GISTs). But there is little information on whether combination of imatinib mesylate (IM) and surgical treatment can prolong survival in the cases with unresectable multiple liver metastases. We report a case of postoperative recurrence of GIST treated by the tyrosine kinase inhibitor IM and surgical treatment. The initial complete response (CR) to treatment continued for 18 mo, but single liver metastasis showed regrowth in the left hepatic lobe during IM treatment. After partial resection of the recurrent tumor, postoperative course was uneventful and the patient has survived without recurrence for 24 mo. Currently, imatinib is the first-line therapy for non-resectable GISTs, but a single agent therapy often leads to tumor resistance. Even if tolerance to imatinib occurs, a combination of imatinib and surgical treatment can prolong survival in some cases as reported here. However, further studies on a large number of cases of recurrent GIST are necessary to evaluate the effectiveness of IM treatment combined with surgery.